BACKGROUND: Emerging viruses like severe acute respiratory syndrome coronavirus (SARS-CoV), Crimean-Congo haemorrhagic fever virus (CCHFV) and Nipah virus (NiV) have been identified to pose a potential threat to transfusion safety. In this study, the ability of the THERAFLEX UV-Platelets and THERAFLEX MB-Plasma pathogen inactivation systems to inactivate these viruses in platelet concentrates and plasma, respectively, was investigated. MATERIALS AND METHODS: Blood products were spiked with SARS-CoV, CCHFV or NiV, and then treated with increasing doses of UVC light (THERAFLEX UV-Platelets) or with methylene blue (MB) plus increasing doses of visible light (MB/light; THERAFLEX MB-Plasma). Samples were taken before and after treatment with each illumination dose and tested for residual infectivity. RESULTS: Treatment with half to three-fourths of the full UVC dose (0·2 J/cm2 ) reduced the infectivity of SARS-CoV (≥3·4 log), CCHFV (≥2·2 log) and NiV (≥4·3 log) to the limit of detection (LOD) in platelet concentrates, and treatment with MB and a fourth of the full light dose (120 J/cm2 ) decreased that of SARS-CoV (≥3·1 log), CCHFV (≥3·2 log) and NiV (≥2·7 log) to the LOD in plasma. CONCLUSION: Our study demonstrates that both THERAFLEX UV-Platelets (UVC) and THERAFLEX MB-Plasma (MB/light) effectively reduce the infectivity of SARS-CoV, CCHFV and NiV in platelet concentrates and plasma, respectively.
BACKGROUND: Emerging viruses like severe acute respiratory syndrome coronavirus (SARS-CoV), Crimean-Congo haemorrhagic fever virus (CCHFV) and Nipah virus (NiV) have been identified to pose a potential threat to transfusion safety. In this study, the ability of the THERAFLEX UV-Platelets and THERAFLEX MB-Plasma pathogen inactivation systems to inactivate these viruses in platelet concentrates and plasma, respectively, was investigated. MATERIALS AND METHODS: Blood products were spiked with SARS-CoV,CCHFV or NiV, and then treated with increasing doses of UVC light (THERAFLEX UV-Platelets) or with methylene blue (MB) plus increasing doses of visible light (MB/light; THERAFLEX MB-Plasma). Samples were taken before and after treatment with each illumination dose and tested for residual infectivity. RESULTS: Treatment with half to three-fourths of the full UVC dose (0·2 J/cm2 ) reduced the infectivity of SARS-CoV (≥3·4 log), CCHFV (≥2·2 log) and NiV (≥4·3 log) to the limit of detection (LOD) in platelet concentrates, and treatment with MB and a fourth of the full light dose (120 J/cm2 ) decreased that of SARS-CoV (≥3·1 log), CCHFV (≥3·2 log) and NiV (≥2·7 log) to the LOD in plasma. CONCLUSION: Our study demonstrates that both THERAFLEX UV-Platelets (UVC) and THERAFLEX MB-Plasma (MB/light) effectively reduce the infectivity of SARS-CoV,CCHFV and NiV in platelet concentrates and plasma, respectively.
Authors: Alexander I Kostin; Maria N Lundgren; Andrey Y Bulanov; Elena A Ladygina; Karina S Chirkova; Alexander L Gintsburg; Denis Y Logunov; Inna V Dolzhikova; Dmitry V Shcheblyakov; Natalia V Borovkova; Mikhail A Godkov; Alexey I Bazhenov; Valeriy V Shustov; Alina S Bogdanova; Alina R Kamalova; Vladimir V Ganchin; Eugene A Dombrovskiy; Stanislav E Volkov; Nataliya E Drozdova; Sergey S Petrikov Journal: Vox Sang Date: 2021-03-18 Impact factor: 2.996
Authors: Kseniya A Mariewskaya; Anton P Tyurin; Alexey A Chistov; Vladimir A Korshun; Vera A Alferova; Alexey V Ustinov Journal: Molecules Date: 2021-06-29 Impact factor: 4.411
Authors: Johannes Glaab; Neysha Lobo-Ploch; Hyun Kyong Cho; Thomas Filler; Heiko Gundlach; Martin Guttmann; Sylvia Hagedorn; Silke B Lohan; Frank Mehnke; Johannes Schleusener; Claudia Sicher; Luca Sulmoni; Tim Wernicke; Lucas Wittenbecher; Ulrike Woggon; Paula Zwicker; Axel Kramer; Martina C Meinke; Michael Kneissl; Markus Weyers; Ulrike Winterwerber; Sven Einfeldt Journal: Sci Rep Date: 2021-07-19 Impact factor: 4.996